<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01342653</url>
  </required_header>
  <id_info>
    <org_study_id>2009-011162-29</org_study_id>
    <nct_id>NCT01342653</nct_id>
  </id_info>
  <brief_title>Clinical Trial at Neoadjuvant Peritoneal and Systemic Chemotherapy Plus HIPEC in Gastric Carcinomatosis</brief_title>
  <acronym>HIPEC</acronym>
  <official_title>Phase II Multicentric Exploratory Single Cohort Clinical Trial to Assess Efficacy and Safety on a New Treatment Scheme by Systemic and Peritoneal Chemotherapy Plus Cytoreduction and HIPEC Plus Adjuvant Treatment in Patients With Peritoneal Carcinomatosis From Gastric Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital General Universitario Gregorio Marañon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Instituto de Salud Carlos III</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospital General Universitario Gregorio Marañon</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Implementation of a curative strategy of treatment in peritoneal carcinomatosis of gastric
      cancer. The goal is to get 1C level of evidence (patient died with &quot;standard&quot; treatment, with
      this treatment some of them survive) in terms of disease free survival and overall survival.

      Methodology: prospective, phase II, multicentric in Spain. Recruitment of 50 patients(to have
      31 on treatment) in three years. This strategy is based on neoadjuvant systemic plus
      simultaneous intraperitoneal and intravenous chemotherapy(NIPS),to treat peritoneal disease
      by bi-directional approach; next step is cytoreductive surgery and HIPEC. Once patients are
      discharged, they will follow a systemic adjuvant chemotherapy protocol.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with peritoneal carcinomatosis with gastric cancer who meet all inclusion
      criteria(and none of exclusion) will follow the next treatment scheme(40 week period of
      treatment):

      Phase I (after one week of peritoneal catheter implant; total treatment 5-8 weeks):
      intraperitoneal infusion of Docetaxel(30 mg/m2) and Cisplatin (30mg/m2) in 1000 cc of saline.
      Intravenous administration 5-FU (200 mg/m2/Day, 7 days a week for 2 weeks) simultaneously
      with 2 cycles of Intraperitoneal administration.

      These patients receive between four and six cycles of NIPS. Until phase II 4-6 weeks.

      Phase II:cytoreduction (CR) plus HIPEC (total treatment 4 weeks). Maximal efforts to optimum
      cytoreduction.

      HIPEC: intraperitoneal administration: Mytomicin C (15mg/m2)plus Adriamycin (15mg/m2) at
      42-43ºC for 60 minutes.

      Intravenous simultaneously administration 5-FU (400mg/m2) plus Leucovorin (20mg/m2) for 10
      minutes at the beginning of peritoneal perfusion.

      Phase III: adjuvant chemotherapy 8-12 weeks after surgery. Those cases reaching optimum
      cytoreduction (CC0) will be treated with systemic chemotherapy: First day: Docetaxel (75
      mg/m2) Cisplatin (75mg/m2). Days 1-5: 5-FU (750mg/m2/d).
    </textblock>
  </detailed_description>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    unable to reach planned recruitment
  </why_stopped>
  <start_date>January 2011</start_date>
  <completion_date type="Anticipated">January 2017</completion_date>
  <primary_completion_date type="Anticipated">January 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>disease free survival</measure>
    <time_frame>36 months</time_frame>
    <description>patients who reached optimum cytoreduction (CC0)after Phase II and eligible to complete adjuvant treatment(Phase III).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>progression free survival</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival in patients with CC0</measure>
    <time_frame>36 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival in patients who did not reach optimum cytoreduction</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>morbidity and mortality</measure>
    <time_frame>first 30 days after surgery procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life after phase I and Phase II</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Peritoneal Carcinomatosis</condition>
  <condition>Gastric Cancer</condition>
  <arm_group>
    <arm_group_label>NIPS plus HIPEC plus adjuvant chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Intraperitoneal and systemic chemotherapy plus maximum cytoreduction plus HIPEC</intervention_name>
    <description>see Design</description>
    <arm_group_label>NIPS plus HIPEC plus adjuvant chemotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men and women aged 18-65 years old

          -  Histological Evidence of peritoneal carcinomatosis from gastric cancer

          -  No distance metastasis

          -  ECOG 0-1-2

          -  No contraindication for complex surgery

          -  no other malign disease except skin cancer (different from melanoma or cervix cancer
             CIN III)

          -  willing to consent and sign ICF.

        Exclusion Criteria:

          -  No Histological Evidence of peritoneal carcinomatosis from gastric cancer

          -  Previous Gastrectomy due to gastric cancer.

          -  Patients with gastric cancer and previous systemic chemotherapy

          -  Peritoneal recurrence due to gastric cancer.

          -  Distance metastasis

          -  SP &gt;2 at recruitment or SP&gt;1 at surgery

          -  previous radiotherapy treatment

          -  pregnant or breastfeeding women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hospital Universitario de Fuenlabrada</name>
      <address>
        <city>Fuenlabrada</city>
        <state>Madrid</state>
        <zip>28942</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario Gregorio Marañon</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Oncologico MD Anderson International España</name>
      <address>
        <city>Madrid</city>
        <zip>28033</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 26, 2011</study_first_submitted>
  <study_first_submitted_qc>April 26, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 27, 2011</study_first_posted>
  <last_update_submitted>November 18, 2016</last_update_submitted>
  <last_update_submitted_qc>November 18, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 21, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Peritoneal</keyword>
  <keyword>Carcinomatosis</keyword>
  <keyword>Gastric</keyword>
  <keyword>Cancer</keyword>
  <keyword>NIPS</keyword>
  <keyword>HIPEC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
    <mesh_term>Carcinoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

